173 related articles for article (PubMed ID: 21102418)
21. Brachyury oncogene is a prognostic factor in high-risk testicular germ cell tumors.
Pinto F; Cárcano FM; da Silva ECA; Vidal DO; Scapulatempo-Neto C; Lopes LF; Reis RM
Andrology; 2018 Jul; 6(4):597-604. PubMed ID: 29749711
[TBL] [Abstract][Full Text] [Related]
22. Notochordal Tumors: An Update on Molecular Pathology with Therapeutic Implications.
Yamaguchi T; Imada H; Iida S; Szuhai K
Surg Pathol Clin; 2017 Sep; 10(3):637-656. PubMed ID: 28797506
[TBL] [Abstract][Full Text] [Related]
23. Testicular mixed germ cell tumors: a morphological and immunohistochemical study using stem cell markers, OCT3/4, SOX2 and GDF3, with emphasis on morphologically difficult-to-classify areas.
Gopalan A; Dhall D; Olgac S; Fine SW; Korkola JE; Houldsworth J; Chaganti RS; Bosl GJ; Reuter VE; Tickoo SK
Mod Pathol; 2009 Aug; 22(8):1066-74. PubMed ID: 19396148
[TBL] [Abstract][Full Text] [Related]
24. Diagnosing an extra-axial chordoma of the proximal tibia with the help of brachyury, a molecule required for notochordal differentiation.
O'donnell P; Tirabosco R; Vujovic S; Bartlett W; Briggs TW; Henderson S; Boshoff C; Flanagan AM
Skeletal Radiol; 2007 Jan; 36(1):59-65. PubMed ID: 16810540
[TBL] [Abstract][Full Text] [Related]
25. Wnt suppressor and stem cell regulator TCF7L1 is a sensitive immunohistochemical marker to differentiate testicular seminoma from non-seminomatous germ cell tumor.
Bu L; Yang Q; McMahon L; Xiao GQ; Li F
Exp Mol Pathol; 2019 Oct; 110():104293. PubMed ID: 31381875
[TBL] [Abstract][Full Text] [Related]
26. Brachyury gene copy number gain and activation of the PI3K/Akt pathway: association with upregulation of oncogenic Brachyury expression in skull base chordoma.
Otani R; Mukasa A; Shin M; Omata M; Takayanagi S; Tanaka S; Ueki K; Saito N
J Neurosurg; 2018 May; 128(5):1428-1437. PubMed ID: 28753115
[TBL] [Abstract][Full Text] [Related]
27. Generation of chordoma cell line JHC7 and the identification of Brachyury as a novel molecular target.
Hsu W; Mohyeldin A; Shah SR; ap Rhys CM; Johnson LF; Sedora-Roman NI; Kosztowski TA; Awad OA; McCarthy EF; Loeb DM; Wolinsky JP; Gokaslan ZL; Quiñones-Hinojosa A
J Neurosurg; 2011 Oct; 115(4):760-9. PubMed ID: 21699479
[TBL] [Abstract][Full Text] [Related]
28. PAX2 and PAX8 expression in primary and metastatic renal tumors: a comprehensive comparison.
Ozcan A; de la Roza G; Ro JY; Shen SS; Truong LD
Arch Pathol Lab Med; 2012 Dec; 136(12):1541-51. PubMed ID: 23194047
[TBL] [Abstract][Full Text] [Related]
29. MAGEC2 is a sensitive and novel marker for seminoma: a tissue microarray analysis of 325 testicular germ cell tumors.
Bode PK; Barghorn A; Fritzsche FR; Riener MO; Kristiansen G; Knuth A; Moch H
Mod Pathol; 2011 Jun; 24(6):829-35. PubMed ID: 21780320
[TBL] [Abstract][Full Text] [Related]
30. Brachyury: A sensitive marker, but not a prognostic factor, for skull base chordomas.
Wang K; Tian K; Wang L; Wu Z; Ren C; Hao S; Feng J; Li J; Wan H; Jia G; Zhang L; Zhang J
Mol Med Rep; 2015 Sep; 12(3):4298-4304. PubMed ID: 26099340
[TBL] [Abstract][Full Text] [Related]
31. SALL4 is a novel diagnostic marker for testicular germ cell tumors.
Cao D; Li J; Guo CC; Allan RW; Humphrey PA
Am J Surg Pathol; 2009 Jul; 33(7):1065-77. PubMed ID: 19390421
[TBL] [Abstract][Full Text] [Related]
32. Molecular characterization of chordoma xenografts generated from a novel primary chordoma cell source and two chordoma cell lines.
Karikari IO; Gilchrist CL; Jing L; Alcorta DA; Chen J; Richardson WJ; Gabr MA; Bell RD; Kelley MJ; Bagley CA; Setton LA
J Neurosurg Spine; 2014 Sep; 21(3):386-93. PubMed ID: 24905390
[TBL] [Abstract][Full Text] [Related]
33. Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas.
Vujovic S; Henderson S; Presneau N; Odell E; Jacques TS; Tirabosco R; Boshoff C; Flanagan AM
J Pathol; 2006 Jun; 209(2):157-65. PubMed ID: 16538613
[TBL] [Abstract][Full Text] [Related]
34. Expression of brachyury in hemangioblastoma: potential use in differential diagnosis.
Barresi V; Vitarelli E; Branca G; Antonelli M; Giangaspero F; Barresi G
Am J Surg Pathol; 2012 Jul; 36(7):1052-7. PubMed ID: 22446946
[TBL] [Abstract][Full Text] [Related]
35. p63, CK7, PAX8 and INI-1: an optimal immunohistochemical panel to distinguish poorly differentiated urothelial cell carcinoma from high-grade tumours of the renal collecting system.
Carvalho JC; Thomas DG; McHugh JB; Shah RB; Kunju LP
Histopathology; 2012 Mar; 60(4):597-608. PubMed ID: 22260386
[TBL] [Abstract][Full Text] [Related]
36. PAX 8 expression in non-neoplastic tissues, primary tumors, and metastatic tumors: a comprehensive immunohistochemical study.
Ozcan A; Shen SS; Hamilton C; Anjana K; Coffey D; Krishnan B; Truong LD
Mod Pathol; 2011 Jun; 24(6):751-64. PubMed ID: 21317881
[TBL] [Abstract][Full Text] [Related]
37. Targeted brachyury degradation disrupts a highly specific autoregulatory program controlling chordoma cell identity.
Sheppard HE; Dall'Agnese A; Park WD; Shamim MH; Dubrulle J; Johnson HL; Stossi F; Cogswell P; Sommer J; Levy J; Sharifnia T; Wawer MJ; Nabet B; Gray NS; Clemons PA; Schreiber SL; Workman P; Young RA; Lin CY
Cell Rep Med; 2021 Jan; 2(1):100188. PubMed ID: 33521702
[TBL] [Abstract][Full Text] [Related]
38. ZBTB16: a novel sensitive and specific biomarker for yolk sac tumor.
Xiao GQ; Li F; Unger PD; Katerji H; Yang Q; McMahon L; Burstein DE
Mod Pathol; 2016 Jun; 29(6):591-8. PubMed ID: 26916077
[TBL] [Abstract][Full Text] [Related]
39. Distinguishing chordoid meningiomas from their histologic mimics: an immunohistochemical evaluation.
Sangoi AR; Dulai MS; Beck AH; Brat DJ; Vogel H
Am J Surg Pathol; 2009 May; 33(5):669-81. PubMed ID: 19194275
[TBL] [Abstract][Full Text] [Related]
40. The use of immunohistochemistry in the diagnosis of metastatic clear cell renal cell carcinoma: a review of PAX-8, PAX-2, hKIM-1, RCCma, and CD10.
Sangoi AR; Karamchandani J; Kim J; Pai RK; McKenney JK
Adv Anat Pathol; 2010 Nov; 17(6):377-93. PubMed ID: 20966644
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
